Search Bar & Filters
Found 57 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying sacituzumab tirumotecan, alone or combined with other treatments, to understand its safety and how it affects certain advanced or unresectable gastrointestinal cancers. These include colorectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. The study aims to evaluate how well the cancer responds to treatment and to monitor any side effects or adverse events over time. Participants will receive sacituzumab tirumotecan either as a single agent or combined with chemotherapy, cisplatin, and pembrolizumab in different dosing schedules. Treatments are given by intravenous infusions every 2 or 3 weeks depending on the study group, continuing until the cancer worsens or treatment is not tolerated. Rescue medications and supportive care are provided to manage side effects during the treatment period. Throughout the study, participants will be closely monitored with regular visits for safety and effectiveness assessments. Researchers will track dose-limiting toxicities, adverse events, treatment discontinuations, and tumor response using established criteria. The study may last up to approximately 63 months, allowing long-term observation of survival and progression-free outcomes. Participants will also receive various laboratory tests and supportive care as needed during this period.
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.
Actively Recruiting
Researchers are evaluating AZD4045, an allogeneic CAR-T therapy targeting B Cell Maturation Antigen BCMA, for adults with relapsed or refractory multiple myeloma RRMM. This Phase III modular study aims to assess the safety, tolerability, preliminary efficacy, and cellular kinetics of AZD4045 alone and in combination with daratumumab and aldesleukin. The goal is also to determine the recommended dose for Phase 2 treatment. The study includes two treatment modules AZD4045 as a monotherapy and AZD4045 combined with daratumumab and aldesleukin. Participants receive these therapies under medical supervision, with dosing designed to evaluate safety and effectiveness over time. Both modules are conducted in parallel to compare outcomes and cellular behavior. During the trial, participants will undergo regular monitoring for adverse events, dose-limiting toxicities, and treatment responses through clinical evaluations and laboratory tests. Researchers will measure objective and complete response rates, duration and time to response, and track CAR transgene levels and other cellular kinetics parameters for up to two years. Safety and efficacy data will be collected throughout the study period, which may last several years.
Actively Recruiting
Researchers are studying Friedreichs Ataxia FA, a genetic condition, to assess the safety, tolerability, and how the body processes a drug called DT-216P2. This phase 12 open-label trial focuses on understanding these factors when the drug is given in multiple increasing doses to people with FA. The study is sponsored by Design Therapeutics, Inc. and aims to gather important information about the treatments effects in this patient group. Participants will receive DT-216P2 through subcutaneous under the skin or intravenous into a vein administration in varying doses. The study includes multiple dose levels to observe the drugs behavior and side effects up to 12 weeks. There is no placebo group, and all participants will be treated with DT-216P2 during the study period, which starts in June 2025 and is planned to conclude by March 2027. During the study, participants will be closely monitored for any side effects or adverse events, with particular attention to treatment-emergent adverse events up to week 12. Researchers will also measure drug levels in the body, including maximum concentration and how long it stays in the system. Frataxin protein levels, important in FA, will be checked before and after treatment. Participants will be regularly assessed for safety and treatment effects throughout the study duration.
Actively Recruiting
Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.
Actively Recruiting
Researchers are evaluating the safety and tolerability of three investigational drugs AZD2284, AZD2287, and AZD2275, in men with metastatic castration-resistant prostate cancer. This first-in-human, open-label Phase I trial includes two parts Part A focuses on imaging to find the best dosing strategy for AZD2287 with or without AZD2275 pre-administration. Part B involves dose escalation of AZD2284 to assess safety, tolerability, and efficacy, including expansion cohorts to explore treatment effects further. Participants receive AZD2287 and may receive AZD2275 depending on the dosing strategy determined in Part A. Eligible participants then receive escalating doses of AZD2284 in Part B. The trial includes several dosing levels and expansion cohorts to characterize safety and efficacy. The study is designed sequentially, with imaging and dosing phases informing each other to optimize treatment administration. During the trial, participants undergo imaging scans such as SPECTCT and planar imaging to evaluate drug distribution and tumor uptake. Researchers monitor adverse events and dose-limiting toxicities up to five years, along with various laboratory tests and pharmacokinetic assessments. Outcome measures include overall response rates, prostate-specific antigen PSA changes, progression-free survival, and overall survival. The studys total duration extends up to five years for long-term safety and effectiveness monitoring.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of up to three doses of KIO-301 given by injection into both eyes every six weeks in adults with late-stage retinitis pigmentosa RP. This study focuses on patients with very limited or no light perception vision, including those classified as No Light Perception or Low Vision. Participants will be randomly assigned to receive either 50 micrograms or 100 micrograms of KIO-301, or a placebo, all administered by intravitreal injection in both eyes three times every six weeks. The main study includes a 12-week treatment period followed by a 12-week follow-up for monitoring. Those who received placebo may opt to join an additional 24-week open-label extension phase. Throughout the study, participants will attend visits every three weeks for safety, tolerability, pharmacokinetic, and efficacy assessments. The screening period can last up to 45 days, and total participation in the main study may last up to 30 weeks, with additional time if joining the extension. Researchers will closely monitor vision changes and side effects to assess the treatments impact and safety.
Actively Recruiting
Researchers are studying the effects of AZD0120, an autologous dual-targeting CAR-T therapy aimed at BCMA and CD19, compared with autologous stem cell transplant ASCT in people newly diagnosed with multiple myeloma who are eligible for transplant. This open-label, randomized Phase III trial aims to measure progression-free survival and the rate of minimal residual disease negative complete response over up to 13 years. Participants are assigned to one of two treatment groups. Arm A receives lymphodepletion with cyclophosphamide and fludarabine over three days, followed by a single infusion of AZD0120 CAR-T cells, then up to two years of lenalidomide maintenance therapy. Arm B receives high-dose melphalan conditioning for 24 to 48 hours followed by ASCT and then the same lenalidomide maintenance regimen for up to two years. The study includes a long-term follow-up period lasting up to 15 years after the last AZD0120 infusion. Throughout the study, participants undergo regular monitoring, including assessments of disease progression and response according to established criteria. Researchers evaluate outcomes such as progression-free survival, complete and overall response rates, duration of response, and safety over approximately 13 years. Participants may expect study visits and evaluations aligned with treatment and follow-up schedules to track their health and treatment effects during this extended period.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of a one-time intravitreal injection of SAR446597 in people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This Phase 12, two-part, multicenter study aims to understand how the treatment works and its potential benefits over approximately two years, followed by an additional three-year extended follow-up period. Participants will receive a single injection of SAR446597 into the eye or a sham injection, depending on the study part and dose group. Multiple dose levels of SAR446597 will be tested in different participant cohorts, with some receiving the active treatment and others receiving a sham as a control. Part I is open-label, while Part II involves randomized dosing and sham control groups. During the study, participants will be monitored for treatment side effects, changes in vision, and the size of GA lesions using visual acuity tests and lesion measurements at baseline, one year, and two years. Safety assessments will continue through the extended follow-up phase. The study also tracks serious and non-serious adverse events up to two years after treatment, with a total study duration of about five years per participant.
1-10 of 57
1